Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 15/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.35 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556084 | 0.82 | OPRK1 (0.42) | OPRD1OPRK1OPRM1RORCAKR1B10 | |
| SCHEMBL16423307 | 0.78 | RORC (0.42) | OPRD1OPRK1OPRM1RORCAKR1B10 | |
| SCHEMBL556661 | 0.77 | RORC (0.40) | OPRD1OPRK1OPRM1RORCAKR1B10 | |
| SCHEMBL16422928 | 0.75 | RORC (0.39) | OPRD1OPRK1OPRM1RORCAKR1B10 | |
| SCHEMBL534235 | 0.75 | OPRK1 (0.35) | OPRD1OPRK1OPRM1 | |
| SCHEMBL533916 | 0.74 | RORC (0.39) | OPRD1OPRK1OPRM1RORCAKR1B10 | |
| SCHEMBL533915 | 0.74 | RORC (0.39) | OPRD1OPRK1OPRM1RORCAKR1B10 | |
| SCHEMBL5379982 | 0.70 | AKR1B10 (0.47) | OPRD1OPRK1OPRM1RORCAKR1B10 | |
| SCHEMBL16434896 | 0.67 | ALK (0.47) | RORC | |
| SCHEMBL16544581 | 0.65 | RORC (0.40) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-2413941-A1 | RENIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | OPRD1 1410/4885OPRK1 980/4885OPRM1 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.